7096 — StemCell Institute Income Statement

0.000.00%

Last trade - 00:00

HealthcareSmall CapFalling Star

Annual income statement for StemCell Institute, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	Yuho	Yuho	Yuho	Tanshin
Standards:	JAS	JAS	JAS	JAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,410	1,782	2,091	2,481	2,679
Cost of Revenue
Gross Profit	924	1,111	1,336	1,576	1,692
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	1,324	1,555	1,815	2,066	2,261
Operating Profit	85.9	227	276	415	419
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	91.4	213	279	441	566
Provision for Income Taxes
Net Income After Taxes	62.4	134	198	311	386
Net Income Before Extraordinary Items
Net Income	62.4	134	198	311	386
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	62.4	134	198	311	386
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	6.15	13.1	20.8	30.2	37.7
Dividends per Share
Special Dividends per Share